These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19690598)

  • 1. [Positron emission tomography in neuroendocrine tumours].
    Biermann M; Johnsen B; Sørbye H; Følling M; Sundin A; Bach-Gansmo T
    Tidsskr Nor Laegeforen; 2009 Aug; 129(15):1474-7. PubMed ID: 19690598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
    Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
    Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
    Chan DL; Pavlakis N; Schembri GP; Bernard EJ; Hsiao E; Hayes A; Barnes T; Diakos C; Khasraw M; Samra J; Eslick E; Roach PJ; Engel A; Clarke SJ; Bailey DL
    Theranostics; 2017; 7(5):1149-1158. PubMed ID: 28435454
    [No Abstract]   [Full Text] [Related]  

  • 4. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear medicine imaging of neuroendocrine tumours.
    Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
    Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
    Chua S; Gnanasegaran G; Cook GJ
    Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional imaging of neuroendocrine tumours with PET.
    Mottaghy FM; Reske SN
    Pituitary; 2006; 9(3):237-42. PubMed ID: 17036194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in PET for the detection of endocrine tumours.
    Eriksson B; Orlefors H; Oberg K; Sundin A; Bergström M; Långström B
    Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):311-24. PubMed ID: 15763703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sensitivity of PET with 18F-fluorodesoxyglucose in the diagnosis of neuroendocrine tumors of the lungs].
    Tlostanova MS; Petrun'kin AM
    Vopr Onkol; 2013; 59(4):505-8. PubMed ID: 24032228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-DOPA PET/CT and neuroendocrine tumours.
    Nanni C; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):509-13. PubMed ID: 16912994
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
    Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
    Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging neuroendocrine tumours with radionuclide techniques.
    Gnanasegaran G; O'Doherty MJ
    Minerva Endocrinol; 2008 Jun; 33(2):105-26. PubMed ID: 18425057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging for neuroendocrine tumours.
    Antwi K; Nicolas G; Wild D; Christ E
    Swiss Med Wkly; 2019 Feb; 149():w20017. PubMed ID: 30852831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostics of neuroendocrine tumours.
    Hodolic M; Fettich J; Banti E; Chondrogiannis S; Al-Nahhas A; Rubello D
    In Vivo; 2010; 24(5):771-4. PubMed ID: 20952747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Supporting Role of (18)FDG-PET in Patients with Neuroendocrine Tumors.
    Howe JR
    Ann Surg Oncol; 2015 Jul; 22(7):2107-9. PubMed ID: 25777088
    [No Abstract]   [Full Text] [Related]  

  • 17. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.
    Binderup T; Knigge U; Loft A; Federspiel B; Kjaer A
    Clin Cancer Res; 2010 Feb; 16(3):978-85. PubMed ID: 20103666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of NETs with PET radiopharmaceuticals.
    Ambrosini V; Tomassetti P; Franchi R; Fanti S
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):16-23. PubMed ID: 20168283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
    Oberg K; Eriksson B
    Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.